Approaches to reconstruction of inferior vena cava by


Journal

World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448

Informations de publication

Date de publication:
21 Aug 2022
Historique:
received: 11 02 2022
revised: 10 06 2022
accepted: 25 07 2022
entrez: 26 9 2022
pubmed: 27 9 2022
medline: 28 9 2022
Statut: ppublish

Résumé

Hepatic alveolar echinococcosis (AE) is most commonly found in retrohepatic inferior vena cava (RHIVC). To propose reasonable RHICV reconstruction strategies for We retrospectively summarized the clinical data of 114 patients diagnosed with hepatic AE who treated by ELRA in our department. A total of 114 patients were divided into three groups according to the different reconstruction methods of RHIVC: Group A with original RHIVC being repaired and reconstructed ( All patients were routinely followed up for a median duration of 52 (range, 12-125) mo. The 30 d mortality rate was 7.0% (8/114) and 7 patients died within 90 d. Among all subjects, the inferior vena cava (IVC)-related complication rates were 17.5% (11/63) in group A and 16.3% (7/43) in group B. IVC stenosis was found in 12 patients (10.5%), whereas thrombus was formed in 6 patients (5.3%). Twenty-two patients had grade III or higher complications, with the complication rates being 17.2%, 16.3%, and 57.1% in the three groups. The average postoperative hospital stay in the three groups was 32.3 ± 19.8, 26.7 ± 18.2, and 51.3 ± 29.4 d ( ELRA can be considered a safe and feasible option for end-stage hepatic AE patients with RHIVC infiltration. The RHIVC reconstruction methods should be selected appropriately depending on the defect degree of AE lesions in IVC lumen. The RHIVC resection without any reconstruction method should be considered with caution.

Sections du résumé

BACKGROUND BACKGROUND
Hepatic alveolar echinococcosis (AE) is most commonly found in retrohepatic inferior vena cava (RHIVC).
AIM OBJECTIVE
To propose reasonable RHICV reconstruction strategies for
METHODS METHODS
We retrospectively summarized the clinical data of 114 patients diagnosed with hepatic AE who treated by ELRA in our department. A total of 114 patients were divided into three groups according to the different reconstruction methods of RHIVC: Group A with original RHIVC being repaired and reconstructed (
RESULTS RESULTS
All patients were routinely followed up for a median duration of 52 (range, 12-125) mo. The 30 d mortality rate was 7.0% (8/114) and 7 patients died within 90 d. Among all subjects, the inferior vena cava (IVC)-related complication rates were 17.5% (11/63) in group A and 16.3% (7/43) in group B. IVC stenosis was found in 12 patients (10.5%), whereas thrombus was formed in 6 patients (5.3%). Twenty-two patients had grade III or higher complications, with the complication rates being 17.2%, 16.3%, and 57.1% in the three groups. The average postoperative hospital stay in the three groups was 32.3 ± 19.8, 26.7 ± 18.2, and 51.3 ± 29.4 d (
CONCLUSION CONCLUSIONS
ELRA can be considered a safe and feasible option for end-stage hepatic AE patients with RHIVC infiltration. The RHIVC reconstruction methods should be selected appropriately depending on the defect degree of AE lesions in IVC lumen. The RHIVC resection without any reconstruction method should be considered with caution.

Identifiants

pubmed: 36159005
doi: 10.3748/wjg.v28.i31.4351
pmc: PMC9453774
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4351-4362

Informations de copyright

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict-of-interest statement: The authors have no conflicts of interest to declare.

Références

Expert Rev Anti Infect Ther. 2016 Dec;14(12):1179-1194
pubmed: 27686694
Medicine (Baltimore). 2015 Feb;94(7):e514
pubmed: 25700312
Transplant Proc. 2021 Mar;53(2):661-664
pubmed: 33139037
Medicine (Baltimore). 2019 Mar;98(11):e14706
pubmed: 30882634
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Langenbecks Arch Surg. 2003 Sep;388(4):231-8
pubmed: 12905036
HPB (Oxford). 2019 Sep;21(9):1219-1229
pubmed: 30782476
Chin Med J (Engl). 2011 Sep;124(18):2813-7
pubmed: 22040485
Clin Microbiol Rev. 2019 Feb 13;32(2):
pubmed: 30760475
Infect Dis Poverty. 2017 Nov 21;6(1):161
pubmed: 29157312
PLoS Negl Trop Dis. 2010 Jun 22;4(6):e722
pubmed: 20582310
Hepatobiliary Pancreat Dis Int. 2004 Nov;3(4):499-503
pubmed: 15567732
Liver Transpl. 2007 Jun;13(6):924-6
pubmed: 17538987
Eur J Gastroenterol Hepatol. 2000 Mar;12(3):327-36
pubmed: 10750654
BMC Surg. 2020 Mar 24;20(1):56
pubmed: 32209078
J Hepatol. 2011 Nov;55(5):1025-33
pubmed: 21354448
Lancet. 2003 Oct 18;362(9392):1295-304
pubmed: 14575976
Surgery. 2019 May;165(5):889-896
pubmed: 30591376
Chin Med J (Engl). 2019 Jul 5;132(13):1623-1624
pubmed: 31205076
J Surg Oncol. 2018 Jul;118(1):127-137
pubmed: 29878363
Am J Transplant. 2016 Feb;16(2):615-24
pubmed: 26460900
Clin Gastroenterol Hepatol. 2007 Feb;5(2):152-9
pubmed: 17157079
Sci Rep. 2019 Jul 1;9(1):9419
pubmed: 31263143
PLoS Negl Trop Dis. 2017 Jul 17;11(7):e0005801
pubmed: 28715408
Acta Trop. 1975;32(3):273-6
pubmed: 1988
Hepatology. 1990 Sep;12(3 Pt 1):617-8
pubmed: 2401464
Transplantation. 2003 Mar 27;75(6):856-63
pubmed: 12660515
Acta Trop. 2010 Apr;114(1):1-16
pubmed: 19931502
Liver Transpl. 2012 Aug;18(8):955-65
pubmed: 22511404
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Am J Transplant. 2018 Jul;18(7):1668-1679
pubmed: 29232038
J Hepatol. 2018 Nov;69(5):1037-1046
pubmed: 30031886
Ann Surg. 2001 Feb;233(2):242-9
pubmed: 11176131
Clin Microbiol Rev. 2004 Jan;17(1):107-35
pubmed: 14726458
Int J Surg Case Rep. 2020;68:251-256
pubmed: 32199250
Liver Transpl. 2011 Jul;17(7):855-65
pubmed: 21455928
Surgery. 2021 Sep;170(3):822-830
pubmed: 33994007
Adv Parasitol. 2017;96:259-369
pubmed: 28212790
Am Surg. 2021 Mar;87(3):443-449
pubmed: 33026233
Acta Virol. 1975 Nov;19(6):467-72
pubmed: 1991

Auteurs

Yusufukadier Maimaitinijiati (Y)

State Key Laboratory on Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, The First Clinical College, Xinjiang Medical University, Urumqi 830011, Xinjiang Uygur Autonomous Region, China.
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830011, Xinjiang Uygur Autonomous Region, China.

Tuerganaili AJi (T)

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830011, Xinjiang Uygur Autonomous Region, China.

Tie-Min Jiang (TM)

State Key Laboratory on Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, The First Clinical College, Xinjiang Medical University, Urumqi 830011, Xinjiang Uygur Autonomous Region, China.
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830011, Xinjiang Uygur Autonomous Region, China.

Bo Ran (B)

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830011, Xinjiang Uygur Autonomous Region, China.

Ying-Mei Shao (YM)

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830011, Xinjiang Uygur Autonomous Region, China.
Xinjiang Organ Transplant Institution, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830011, Xinjiang Uygur Autonomous Region, China.

Rui-Qing Zhang (RQ)

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830011, Xinjiang Uygur Autonomous Region, China.

Qiang Guo (Q)

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830011, Xinjiang Uygur Autonomous Region, China.

Mao-Lin Wang (ML)

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830011, Xinjiang Uygur Autonomous Region, China.

Hao Wen (H)

State Key Laboratory on Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, The First Clinical College, Xinjiang Medical University, Urumqi 830011, Xinjiang Uygur Autonomous Region, China.
Xinjiang Organ Transplant Institution, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830011, Xinjiang Uygur Autonomous Region, China. surgeon0309@126.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH